2018
Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Eckardt K, Bansal N, Coresh J, Evans M, Grams M, Herzog C, James M, Heerspink H, Pollock C, Stevens P, Tamura M, Tonelli M, Wheeler D, Winkelmayer W, Cheung M, Hemmelgarn B, Participants C, Abu-Alfa A, Anand S, Arici M, Ballew S, Block G, Burgos-Calderon R, Charytan D, Das-Gupta Z, Dwyer J, Fliser D, Froissart M, Gill J, Griffith K, Harris D, Huffman K, Inker L, Jager K, Jun M, Kalantar-Zadeh K, Kasiske B, Kovesdy C, Krane V, Lamb E, Lerma E, Levey A, Levin A, Mauro J, Nash D, Navaneethan S, O’Donoghue D, Obrador G, Pecoits-Filho R, Robinson B, Schäffner E, Segev D, Stengel B, Stenvinkel P, Tangri N, Tentori F, Tsukamoto Y, Turakhia M, Vazquez M, Wang A, Williams A. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2018, 93: 1281-1292. PMID: 29656903, PMCID: PMC5998808, DOI: 10.1016/j.kint.2018.02.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGlomerular filtration rateKidney replacement therapyCKD G4Kidney failureFiltration rateRisk factorsGlobal outcomeTraditional CVD risk factorsCKD Prognosis ConsortiumCVD risk factorsCardiovascular disease eventsPrognosis of patientsOptimal therapeutic strategyControversies ConferenceCohort studyCVD outcomesHeart failureVariable prognosisClinical outcomesTherapeutic challengeKidney diseasePrognostic valueReplacement therapyInternational expert groupPatient preferencesKidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Swanepoel C, Atta M, D’Agati V, Estrella M, Fogo A, Naicker S, Post F, Wearne N, Winkler C, Cheung M, Wheeler D, Winkelmayer W, Wyatt C, Participants C, Abu-Alfa A, Adu D, Agodoa L, Alpers C, Arogundade F, Ashuntantang G, Bagnis C, Bhimma R, Brocheriou I, Cohen A, Cohen K, Cook H, de Seigneux S, Fabian J, Finkelstein F, Haas M, Hamzah L, Hendry B, Imonje V, Jennette J, Kimmel P, Klotman M, Klotman P, Larsen C, McCulloch M, Mosiane P, Nast C, Okpechi I, Ray P, Rosenberg A, Ross M, Ryom L, Truong L, Ulasi I, Vogt L, Zeier M. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2018, 93: 545-559. PMID: 29398134, PMCID: PMC5983378, DOI: 10.1016/j.kint.2017.11.007.Peer-Reviewed Original ResearchConceptsHIV-positive individualsKidney diseaseAntiretroviral therapyHIV infectionImmune complex kidney diseaseKidney disease preventionHIV-associated nephropathyFocal segmental glomerulosclerosisUnique HIVKidney injuryOpportunistic infectionsHIV treatmentClinical guidelinesRenal pathologySegmental glomerulosclerosisGeneral populationRole of geneticsGlobal outcomeDisease preventionNatural historyInfectious diseasesDiseaseInfectionGenetic factorsPrevention
2007
Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1. Radiology 2007, 242: 647-9. PMID: 17213364, DOI: 10.1148/radiol.2423061640.Commentaries, Editorials and Letters